Top

Published in:

01-05-2009 | Hepatobiliary and Pancreatic Tumors

Long-Term Survival and Disease Recurrence Following Portal Vein Embolisation Prior to Major Hepatectomy for Colorectal Metastases

Authors: Viniyendra Pamecha, MS, MRCS, FEBS, Georgios Glantzounis, Niel Davies, Giuseppe Fusai, Dinesh Sharma, Brian Davidson

Published in: Annals of Surgical Oncology | Issue 5/2009

Abstract

Background

Portal vein embolisation (PVE) can be used to increase the remnant liver parenchyma volume before major hepatectomy but may stimulate tumour growth. The pattern of disease recurrence and long-term survival has not been adequately addressed.

Methods

Over a period of 7 years 36 patients underwent preoperative PVE before resection of four or more liver segments for colorectal cancer (CRC) liver metastases. PVE was performed when the future liver remnant (FLR) assessed by magnetic resonance imaging (MRI) scan volumetry was less than 30%. Disease-free and overall survival was compared with a control group (65 patients) undergoing extended right/right hepatectomy for CRC metastases without PVE during the same time period.

Results

PVE was successful in all patients. PVE increased the median FLR volume by 37% [295 ml (22%) to 404 ml (32%), p < 0.0001]. 61% of patients undergoing PVE proceeded to liver resection (n = 22). Twelve patients (33%) developed disease progression following PVE. The 5-year survival after liver resection with PVE was 25%, compared with 50% without PVE. The 5-year disease-free survival was 30% post PVE and 50% without PVE.

Conclusion

We conclude that PVE significantly increases the future liver remnant. Only two-thirds of patients proceed to resection because of disease progression. Long-term survival is less than in patients who do not require PVE. The effect of PVE on tumour growth requires investigation.

Simmonds PC, Primrose JN, Colquitt JL, Garden OJ, Poston GJ, Rees M. Surgical resection of hepatic metastases from colorectal cancer. Br J Cancer. 2006;94(7):982–99.PubMedCrossRef

Schindl MJ, Redhead DN, Fearon KC, Garden OJ, Wigmore SJ. Edinburgh Liver Surgery and Transplantation Experimental Research Group (eLISTER). The value of residual liver volume as a predictor of hepatic dysfunction and infection after major liver resection. Gut. 2005;54(2):289–96.PubMedCrossRef

Melendez J, Ferri E, Zwillman M, et al. Extended hepatic resection: a 6-year retrospectivestudy of risk factors for perioperative mortality. J Am Coll Surg. 2001;192:47–53.PubMedCrossRef

Kinoshita H, Sakai K, Hirohashi K, et al. Preoperative portal vein embolization for hepatocellular carcinoma. World J Surg. 1986;10:803–8.PubMedCrossRef

Makuuchi M, Thai BL, Takayasu K, et al. Preoperative portal embolizationto increase safety of major hepatectomy for hilar bile duct carcinoma: a preliminary report. Surgery. 1990;107:521–7.PubMed

Azoulay D, Castaing D, Smail A, et al. Resection of nonresectable liver metastases from colorectal cancer after percutaneous portal vein embolization. Ann Surg. 2000;231:480–6.PubMedCrossRef

Elias D, De Baere T, Roche A, et al. During liver regeneration following right portal embolization the growth rate of liver metastases is more rapid than that of the liver parenchyma. Br J Surg. 1999;86:784–8.PubMedCrossRef

Jaeck D, Bachellier P, Nakano H, Oussoultzoglou E, Weber JC, Wolf P, et al. One or two stage hepatectomy combined with portal vein embolisation for initially nonresectable colorectal liver metastases. Am J Surg. 2003;185(3):221–9.PubMedCrossRef

Lindner P, Cahlin C, Friman S, Hafstrome L, Klingenstierna H, Lonn L, et al. Extended right sided liver resection for colorectal liver metastases-impact of percutaneous portal venous embolisation. Eur J Surg Oncol. 2006;32(3):292–6.PubMedCrossRef

10.

Beal I, Anthony S, Papadopoulou A, Huthins R, Fusai K, Begent R, et al. The effect of chemotherapy in patients undergoing portal vein embolisation prior to hepatic resection for colorectal liver metastases. Br J Radiol. 2006;79(942):473–8.PubMedCrossRef

11.

Bhattacharjya S, Aggarwal R, Davidson BR. Intense follow up after liver resection for colorectal metastases—results of combined serial tumor markers estimations and computed tomography of the chest and abdomen—a prospective study. Br J Cancer. 2006;95:21–6.PubMedCrossRef

12.

Ribero D, Abdalla EK, Madoff DC, Donadon M, Loyer EM, Vauthey JN. Portal vein embolization before major hepatectomy and its effects on regeneration, resectability and outcome. Br J Surg. 2007;94:1386–94.PubMedCrossRef

13.

Giraudo G, Greget M, Oussoultzoglou E, Rosso E, Bachellier P, Jaeck D. Preoperative contralateral portal vein embolization before major hepatic resection is a safe and efficient procedure: a large single institution experience. Surgery. 2008;143(4):476–82.PubMedCrossRef

14.

Ferrero A, Viganò L, Polastri R, Muratore A, Eminefendic H, Regge D, et al. Postoperative liver dysfunction and future remnant liver: where is the limit? Results of a prospective study. World J Surg. 2007;31(8):1643–51.PubMedCrossRef

15.

Zorzi D, Laurent A, Pawlik TM, Lauwers GY, Vauthey JN, Abdalla EK. Chemotherapy-associated hepatotoxicity and surgery for colorectal liver metastases. Br J Surg. 2007;94(3):274–86.PubMedCrossRef

16.

Hewes JC, Dighe S, Morris RW, Hutchins RR, Bhattacharya S, Davidson BR. Preoperative chemotherapy and the outcome of liver resection for colorectal metastases. World J Surg. 2007;31(2):353–64.PubMedCrossRef

17.

Dinant S, de Graaf W, Verwer BJ, Bennink RJ, van Lienden KP, Gouma DJ, et al. Risk assessment of posthepatectomy liver failure using hepatobiliary scintigraphy and CT volumetry. J Nucl Med. 2007;48(5):685–92.PubMedCrossRef

18.

Mueller L, Hillert C, Möller L, Krupski-Berdien G, Rogiers X, Broering DC. Major hepatectomy for colorectal metastases: is preoperative portal occlusion an oncological risk factor? Ann Surg Oncol. 2008;15(7):1908–17.PubMedCrossRef

19.

Kokudo N, Tada K, Seki M, et al. Proliferative activity of intrahepatic colorectal metastases after preoperative hemihepatic portal vein embolization. Hepatology. 2001;34:267–272.PubMedCrossRef

20.

Pamecha V, Levene A, Federica G, Dhillon A, Davidson BR. Effect of portal vein embolisation on tumor morphology of colorectal cancer liver metastases. HPB (Oxford). 2008;10(S1):227–8.

21.

Adam R, Pascal G, Castaing D, Azoulay D, Delvart V, Paule B, et al. Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases? Ann Surg. 2004;240(6):1052–61; discussion 1061–4.PubMedCrossRef

22.

Wang X, Hershman DL, Abrams JA, Feingold D, Grann VR, Jacobson JS, et al. Predictors of survival after hepatic resection among patients with colorectal liver metastasis. Br J Cancer. 2007;97(12):1606–12.PubMedCrossRef

23.

Abdalla EK, Vauthey JN. Improved survival after resection of colorectal liver metastases. J Clin Oncol. 2006;24(17):2679.PubMedCrossRef

24.

Covey AM, Brown KT, Jarnagin WR, Brody LA, Schwartz L, Tuorto S, et al. Combined portal vein embolization and neoadjuvant chemotherapy as a treatment strategy for resectable hepatic colorectal metastases. Ann Surg. 2008;247(3):451–5.PubMedCrossRef

25.

Goéré D, Farges O, Leporrier J, Sauvanet A, Vilgrain V, Belghiti J. Chemotherapy does not impair hypertrophy of the left liver after right portal vein obstruction. J Gastrointest Surg. 2006;10(3):365–70.PubMedCrossRef

26.

Zuckerman DS, Clark JW. Systemic therapy for metastatic colorectal cancer: current questions. Cancer. 2008;112(9):1879–91.PubMedCrossRef

27.

Oussoultzoglou E, Bachellier P, Rosso E, Scurtu R, Lucescu I, Greget M, et al. Right portal vein embolization before right hepatectomy for unilobar colorectal liver metastases reduces the intrahepatic recurrence rate. Ann Surg. 2006;244(1):71–79.PubMedCrossRef

Title: Long-Term Survival and Disease Recurrence Following Portal Vein Embolisation Prior to Major Hepatectomy for Colorectal Metastases
Authors: Viniyendra Pamecha, MS, MRCS, FEBS
Georgios Glantzounis
Niel Davies
Giuseppe Fusai
Dinesh Sharma
Brian Davidson
Publication date: 01-05-2009
Publisher: Springer-Verlag
Published in: Annals of Surgical Oncology / Issue 5/2009
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-008-0269-4

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Long-Term Survival and Disease Recurrence Following Portal Vein Embolisation Prior to Major Hepatectomy for Colorectal Metastases

Abstract

Background

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 5/2009

Neoadjuvant and Postoperative Adjuvant Anticancer Chemotherapy in Gastric Cancer

Stage IV Breast Cancer: Is Surgical Resection of Clinical Utility?

Feasibility and Efficacy of Accelerated Weekly Concomitant Boost Postoperative Radiation Therapy Combined with Concomitant Chemotherapy in Patients with Locally Advanced Head and Neck Cancer

Gemicitabine Resistence and Mesenchymal Phenotype

Factors Predictive of Acute Regional Toxicity After Isolated Limb Infusion with Melphalan and Actinomycin D in Melanoma Patients

Sentinel Node Biopsy in Breast Cancer Patients with Large or Multifocal Tumors